The benefit of complete (CR) vs. incomplete revascularization (IR) with drug-eluting stent (DES), unlike with bypass grafting, is not well established in patients with multivessel coronary artery disease (MVD). 
n patients with multivessel coronary artery disease (MVD), revascularization of all diseased vessels or complete revascularization (CR) would be more beneficial than incomplete revascularization (IR) if CR can be achieved and maintained without increased adverse events. In this regard, CR is well known to be associated with better long-term prognosis in MVD patients undergoing coronary artery bypass grafting (CABG). But unlike CABG, percutaneous coronary intervention (PCI) is not always feasible especially for complex lesions and is subject to restenosis. Before the advent of drug-eluting stents (DES), restenosis and need for repeat revascularization was a major limitation for active percutaneous revascularization. Recently, DES have greatly reduced this limitation with improved anti-restenotic efficacy. In the current DES era, PCI is thus increasingly used as an initial revascularization method in patients with MVD, substituting fairly for CABG. However, the benefit of CR vs. IR in patients with MVD undergoing PCI is not well established. As to balloon angioplasty or bare-metal stents (BMS), the benefit of CR vs. IR has been controversial in previous studies. As to DES, only limited reports are available comparing the 2 revascularization strategies.
In this study, we aimed to compare the 2 revascularization strategies, CR and IR, in MVD patients undergoing PCI with DES in terms of long-term clinical outcomes.
I Revascularization Strategy in Multivessel Disease

Methods
Study Population and Definitions
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee, which exempted informed consent.
This was an observational study from the Seoul National University Hospital (SNUH) DES registry, where clinical, angiographic, and procedural characteristics and the results of PCI are recorded at the time of PCI. Consecutive patients who were newly diagnosed as having MVD and who underwent successful PCI using DES between March 2003 and December 2009 were identified from the registry. MVD was defined as the presence of diameter stenosis ≥50% in more than 2 major epicardial coronary arteries or their side branches with a diameter ≥2.5 mm. Successful PCI was defined as the presence of Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow without residual stenosis ≥30% at the end of the procedure. Excluded were patients with acute ST segment elevation myocardial infarction (MI), cardiogenic shock, cardiopulmonary resuscitation, left main coronary artery disease, previous history of any type of revascularization (PCI or CABG), and life-expectancy ≤1 year due to well-defined comorbidities at the time of PCI.
Patients with MVD were divided into 2 groups according to the completeness of revascularization; CR and IR. There are different definitions of CR found in the literature. 1 We adopted a conditional anatomic definition in this study: CR as the absence of diameter stenosis ≥50% in major epicardial coronary arteries or their side branches with a diameter ≥2.5 mm after successful PCI during index admission irrespective of the function or viability of relevant myocardium. The decisions on whether to refer to CABG or perform PCI and whether to perform CR or IR in case of PCI were made by the attending cardiologist without routine prior consultation with surgeons. In case of patients who refused CABG, PCI was performed if it was technically feasible.
Procedures
PCI generally followed standard techniques and guidelines. Predilatation, post-stent adjunctive balloon inflation, and use of a glycoprotein IIb/IIIa inhibitor were all at the operators' discretion. All patients were given aspirin, clopidogrel, and 5,000-10,000 U of intravenous heparin before PCI. The selection of the type of DES (sirolimus-, paclitaxel-, or zotarolimus-eluting stents) was also at the operator's discretion. After PCI, aspirin (100 mg daily) was maintained indefinitely and clopidogrel (75 mg daily) for at least 12 months.
Follow-up
A follow-up angiography was routinely recommended at 6 months after stent implantation. Angiographic and clinical follow-up data were obtained from the registry, electronic medical records, and telephone interviews, if necessary. All patients were finally traced by death data (death date and cause of death) collected and supplied by Statistics Korea (http://mdss. kostat.go.kr). All patients were evaluated for the following adverse events: death, cardiac death, MI, and repeat revascularization. All deaths without a documented specific cause were considered of cardiac origin (eg, death due to senility was considered as cardiac death). The diagnosis of MI was based on the presence of at least 2 of the following findings: acute ischemic symptoms, concentration of cardiac enzymes (creatine kinase and its MB isoenzyme [CK-MB]) at least twice their upper normal limits, and new electrocardiographic changes compatible with MI. Repeat revascularization was defined as any PCI or CABG performed after index admission. All composite endpoints were counted in a hierarchical order.
Statistical Analysis
Opting for CR or IR might be significantly influenced by baseline characteristics. A direct comparison of the 2 groups can be thus misleading. We used propensity score matching to compensate for the potential selection biases. The propensity score was defined as the conditional probability of receiving CR on the basis of observed variables and was computed using logistic regression with CR as a dependent variable, and the baseline characteristics as independent variables with enter method. We matched the nearest neighbors according to the derived propensity scores with a 1:1 ratio.
Survival curves were constructed by using the Kaplan-Meier method and the cumulative event rates were compared using a log rank test. Cox regression analysis was performed to determine the unadjusted and adjusted hazard ratio (HR) of CR for adverse events. In the multivariate Cox regression model, variables that were not significant at P<0.1 were removed by backward elimination. The assumption of a proportional hazard was checked with time-dependent covariates and was found to be reasonable.
Continuous variables were presented as mean ± standard deviation and were compared using Student's t-test or the MannWhitney U test, where appropriate. Categorical variables were presented as raw numbers (percentage) and were compared using the chi-square test or Fisher's exact test, where appropriate.
A 2-sided P<0.05 was considered statistically significant. Statistical tests were carried out with SPSS 14.0K soft ware (SPSS, Chicago, IL, USA).
Results
Baseline Characteristics
Among 994 patients eligible, 845 patients (337 with CR and 508 with IR) had a full set of variables required for multivariate analyses. Their baseline characteristics were quite different according to the revascularization strategy ( Table 1) . We performed multivariate logistic regression analysis with CR as a dependent variable, and the baseline characteristics as independent variables (age, sex, hypertension, diabetes, smoking, dyslipidemia, peripheral vascular disease, cerebrovascular disease, estimated glomerular filtration rate (eGFR), left ventricular ejection fraction (LVEF), acute coronary syndrome, triple vessel disease, left anterior descending coronary artery disease, chronic total occlusion, coronary artery disease prognostic index, 2 type of DES, discharge medications). The independent predictors of CR were a higher coronary artery dis- We selected 275 pairs of patients using propensity score matching with a median probability to receive CR of 0.44 (interquartile range: 0.36-0.50). In the propensity-matched population, there was no difference in the baseline characteristics with standardized differences in the variables all within 10% between patients with CR and IR ( Table 2) .
Clinical Outcomes
A total of 845 patients were followed for a median of 4.0 years (interquartile range: 3.2-4.9 years). The cumulative rate of death was 9.0% in the CR group vs. (Figure S1 ). However, in the Cox regression analysis with preprocedural characteristics, discharge medications, and revascularization strategy as covariates and with the type of DES as strata, CR was not associated with a long-term clinical benefit ( Table 3) . Five hundred and fifty propensity score-matched patients were followed for a median of 3.9 years (inter-quartile range: 3.1-4.8 years). The cumulative rate of death was 7.2% in the CR group vs. 16 Table 3) .
The impact of CR on repeat revascularization in patients without cardiac death or MI was not significant. The adjusted HR of CR for the "pure" repeat revascularization was 1.06 [0.74-1.50] in 805 patients from the total population and 1.10 [0.72-1.68] in 526 patients from the propensity score-matched population.
Other Predictors of Adverse Events
In addition to IR, low eGFR was a common independent predictor of death/MI and cardiac death/MI. Low LVEF was an independent predictor of cardiac death/MI. Diabetes was a common independent predictor of death/MI/repeat revascularization and cardiac death/MI/repeat revascularization. Predictors of each adverse event are listed in Table 4 .
Subgroup Analysis
We analyzed the benefit of CR in the specific high-risk patient subgroups such as diabetes, heart dysfunction with low LVEF (<55%), and renal dysfunction with low eGFR (<60 ml/min) from the propensity score-matched population ( Table 5 ). In the subgroup of low LVEF (n=153), the benefit of CR in reducing cardiac death/MI was larger and more significant than in the whole propensity-matched population. In the diabetes (n=191) and low eGFR (n=170) subgroup, the benefit of CR in reducing cardiac death/MI was maintained. The benefit of CR in reducing death/MI was not significant in these subgroups.
Discussion
In this observational study, CR was associated with a longterm clinical benefit in reducing the 2 serious composite endpoints: death/MI and cardiac death/MI. The observed benefit was mainly derived during the first 1 year, suggesting that the potential beneficiaries were high-risk patients. Indeed, the benefit of CR was even larger and more significant in the low LVEF subgroup and was still maintained in patients from the diabetes and low eGFR subgroups. Furthermore, CR did not increase the rate of repeat revascularization in the survivors from the cardiac death/MI, even though this strategy increased the number of stents from 1.7 to 2.7 per patient, reflecting the excellent efficacy of DES. Conversely, there was not a sig- 
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nificant increase in the rate of the repeat revascularization after IR, reflecting the relatively stable natural course of the residual lesions or the preference of the conservative medical treatment after IR. According to our results, CR should be initially considered primarily to prevent serious adverse events in MVD patients undergoing DES implantation, especially in the high-risk patients with low LVEF and also in patients with diabetes or low eGFR.
Our findings add to current weak evidence on the benefit of CR with DES in reducing serious adverse events. According to Hannan et al, IR increased mortality by 23% (P=0.01), and death and MI by 27% (P=0.002) in the non-matched popula- 3 According to Tamburino et al, CR reduced cardiac death by 83% (P=0.007), and cardiac death or MI by 78% (P=0.007) in the propensitymatched population (n=278) during a median follow up of 2.3 years. 4 On the contrary, Song et al reported the limited benefit of CR in reducing only repeat revascularization in 873 nonmatched and 510 matched patient populations during a median follow up of 3 years. 5 Tamburino et al also reported the benefit of CR in reducing any repeat revascularization by 60% (P=0.0004). There are possible explanations for the difference in the reported benefit of CR among the observational studies. There are certainly differences among studies in the aggressiveness of PCI, rate of referral to CABG, or threshold of a physician to conduct repeated PCI for residual lesions after IR, all of which can significantly affect the characteristics of the included patients and can vary among centers. In this regard, it seems reasonable to apply the result primarily to the center where the data were drawn. One should also interpret the result with caution in that the patients initially treated with percutaneous IR because percutaneous CR or CABG was not feasible might distort the true effect of CR vs. IR, who would have been excluded in a randomized trial. Despite statistical compensation, such a distortion cannot be fully corrected. A randomized trial of MVD including a CABG arm is warranted to resolve such complex issues.
The prognostic implications of CR in patients with MVD undergoing CABG have been extensively evaluated, and it was established as the optimal surgical revascularization strategy.
In fact, despite a few apparently controversial results, 6,7 most surgical series have documented significantly reduced longterm mortality with complete revascularization. 8-12 On the contrary, there has been considerable uncertainty on the clinical impact of CR in patients with MVD undergoing PCI. Among studies including one small randomized trial comparing the outcomes of CR vs. IR in MVD patients undergoing balloon angioplasty or BMS implantation, 7,13-19 only a few most recent observational studies demonstrated the benefit of CR with BMS in terms of long-term survival. 15, 19 As to DES, only a few reports are available including ours, all of which consistently support the benefit of CR, although the extent of the benefit is widely conflicting. 3-5 All these PCI reports available, when taken together, support the improving benefit of CR in MVD patients. This might be due to general advances in the field of PCI. A dramatic improvement in interventional techniques, strategies, devices and medications achieved in the DES era might have resulted in the improved benefit of CR. In this regard, PCI vs. CABG for MVD in the current DES era is to be further tested. 20 The superiority of DES itself, in terms of safety, seems to be challenging. Among reports comparing the safety of DES vs. BMS, a few observational studies and their meta-analysis reported even better safety for using DES. 21, 22 It is quite remarkable that the benefit of CR became even larger and more evident in the low LVEF subgroup and was maintained in the diabetic and low eGFR subgroups despite the number of patients being approximately one-third of the total. The most provocative finding of our report is that such high-risk subgroups seem to be the best beneficiaries of CR with DES in terms of serious adverse events. How to treat diabetics or chronic kidney disease is an important issue but has rarely has been answered up to date.
The cumulative rate of non-cardiac death in our study seems to be high in the IR group. Considering the Kaplan-Meier curves for death in the propensity score-matched population rapidly drifting apart due to very late non-cardiac deaths, the cumulative rate of death in the IR group might have been overestimated. Again, this was a non-randomized observational study and thus the results should be interpreted cautiously with regard to potentially serious selection bias. Although propensity score matching was used, unobserved factors that affect the patient selection can still affect the results. The number of patients included in this study was not enough for robust analysis of the infrequent serious adverse events such as death or cardiac death. The validity of the results from the subgroup analysis depends on that of the main results. Tables 1,3 . Abbreviations as in Table 4 . CHUNG JW et al.
In summary, CR was associated with the benefit in reducing the cardiac death and MI or the composite of these in patients with MVD undergoing PCI with DES. Subgroups with low LVEF or diabetes were the best beneficiaries of CR. However, the benefit did not extend to repeat revascularization and overall adverse cardiac events. This was an observational study and our results cannot be free from potential serious biases, warranting the confirmation of the results by using randomized trials.
